Compare BXMT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | TARS |
|---|---|---|
| Founded | 1966 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 1998 | 2020 |
| Metric | BXMT | TARS |
|---|---|---|
| Price | $12.41 | $76.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $21.38 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.0M | 665.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | ★ 154.70 | 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | N/A | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $12.31 | $53.89 |
| 52 Week High | $20.67 | $91.53 |
| Indicator | BXMT | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 24.34 | 49.22 |
| Support Level | N/A | $60.95 |
| Resistance Level | $14.27 | $79.10 |
| Average True Range (ATR) | 0.34 | 2.72 |
| MACD | -0.05 | -1.10 |
| Stochastic Oscillator | 9.28 | 13.08 |
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.